100 related articles for article (PubMed ID: 23128395)
1. RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine.
Saunders PO; Weiss J; Welschinger R; Baraz R; Bradstock KF; Bendall LJ
Oncogene; 2013 Oct; 32(40):4789-97. PubMed ID: 23128395
[TBL] [Abstract][Full Text] [Related]
2. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia.
Crazzolara R; Cisterne A; Thien M; Hewson J; Baraz R; Bradstock KF; Bendall LJ
Blood; 2009 Apr; 113(14):3297-306. PubMed ID: 19196656
[TBL] [Abstract][Full Text] [Related]
3. RAD001 enhances the radiosensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint.
Yu CC; Hung SK; Liao HF; Lee CC; Lin HY; Lai HC; Li SC; Ho HC; Huang HB; Su YC
Anticancer Res; 2014 Jun; 34(6):2927-35. PubMed ID: 24922656
[TBL] [Abstract][Full Text] [Related]
4. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
Zitzmann K; De Toni EN; Brand S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
Neuroendocrinology; 2007; 85(1):54-60. PubMed ID: 17310129
[TBL] [Abstract][Full Text] [Related]
5. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
Saunders P; Cisterne A; Weiss J; Bradstock KF; Bendall LJ
Haematologica; 2011 Jan; 96(1):69-77. PubMed ID: 20952516
[TBL] [Abstract][Full Text] [Related]
6. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
7. Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.
Zhang X; Zhang S; Liu Y; Liu J; Ma Y; Zhu Y; Zhang J
Eur J Cancer; 2012 Jul; 48(10):1581-92. PubMed ID: 22420943
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage.
Buitrago-Molina LE; Pothiraju D; Lamlé J; Marhenke S; Kossatz U; Breuhahn K; Manns MP; Malek N; Vogel A
Hepatology; 2009 Aug; 50(2):500-9. PubMed ID: 19642171
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
Haritunians T; Mori A; O'Kelly J; Luong QT; Giles FJ; Koeffler HP
Leukemia; 2007 Feb; 21(2):333-9. PubMed ID: 17136116
[TBL] [Abstract][Full Text] [Related]
10. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro effects of RAD001 on bladder cancer.
Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
[TBL] [Abstract][Full Text] [Related]
13. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
[TBL] [Abstract][Full Text] [Related]
15. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
16. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
17. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer.
Homicsko K; Lukashev A; Iggo RD
Cancer Res; 2005 Aug; 65(15):6882-90. PubMed ID: 16061672
[TBL] [Abstract][Full Text] [Related]
18. Cell Cycle-Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells.
Kothari A; Hittelman WN; Chambers TC
Cancer Res; 2016 Jun; 76(12):3553-61. PubMed ID: 27197148
[TBL] [Abstract][Full Text] [Related]
19. The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line.
Tsaur I; Makarević J; Hudak L; Juengel E; Kurosch M; Wiesner C; Bartsch G; Harder S; Haferkamp A; Blaheta RA
Cancer Lett; 2011 Dec; 313(1):84-90. PubMed ID: 21925791
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice.
Welschinger R; Liedtke F; Basnett J; Dela Pena A; Juarez JG; Bradstock KF; Bendall LJ
Exp Hematol; 2013 Mar; 41(3):293-302.e1. PubMed ID: 23178377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
